BD has reported satisfaction with its financial performance for the third quarter of 2017, during which it generated a revenue total of $3.04 billion (2.34 billion pounds).
This represented a year-on-year decrease of 5.1 percent, but this drop was most due to the sale of the company's respiratory solutions business in October 2016. When considered on a comparable, currency-neutral basis, third-quarter revenues grew by 2.4 percent.
“BD has announced strong financial results for the third quarter of 2017.“
Its medical division saw a strong performance from its medication and procedural solutions, diabetes care and pharmaceutical systems units, while the life science segment saw a good performance from its biosciences unit and encouraging growth within diagnostic and preanalytical systems.
Vincent Forlenza, chairman and chief executive officer of BD, said: "We are pleased with our third quarter performance and outlook for fiscal year 2017. We continue to deliver consistent, solid results while driving toward the successful closing of the CR Bard acquisition."
The company continues to estimate that revenues for the full fiscal year 2017 will increase by 4.5 to five percent on a comparable, currency-neutral basis, excluding respiratory solutions and other divestitures closed during 2016.
It has also raised its adjusted diluted earnings per share guidance for the year from $9.42 to $9.47, which represents growth of approximately ten percent.
With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Science